Although a monotherapy using pan-PI3K inhibitors, isoform-selective PI3K inhibitors, and dual PI3K/mTOR inhibitors showed promising anti-proliferative effects in several preclinical ACC models, we observed a lack of efficacy in clinical trials19. This evidence concerns the gene PIK3CB and adrenal cortex carcinoma.